Statement of Principles concerning microscopic polyangiitis (Reasonable Hypothesis) (No. 90 of 2019)

The instrument pivots on a compact set of legal‑medical concepts that determine its application in claims assessment. The core concepts are: the legal identity of microscopic polyangiitis for this instrument; the catalogue of factors that can raise a reasonable hypothesis; the requirement of relationship to relevant service; the time distinctions between clinical onset and clinical worsening; and cross‑reference to other Statements of Principles.

Microscopic polyangiitis (MPA) is defined in medical terms in subsection 7(2): "a necrotising non‑granulomatous vasculitis with few or no immune deposits predominantly affecting small vessels (capillaries, venules or arterioles)" (s7(2)(a)). The instrument expressly excludes polyarteritis nodosa, granulomatosis with polyangiitis (Wegener granulomatosis) and eosinophilic granulomatosis with polyangiitis (Churg‑Strauss syndrome) (s7(2)(b)). The instrument also notes that while MPA attracts ICD‑10‑AM code M31.7, the legal meaning for this instrument is the textual medical definition in s7(2) rather than reliance on the code alone (s7(3)-(4)).

The factors set out in s9 are disjunctive: at least one factor must exist to raise the reasonable hypothesis. They fall into four types: occupational inhalational exposure to respirable crystalline silica with a defined cumulative threshold (2,500 hours) before clinical onset or before clinical worsening (s9(1) and s9(4)); presence of silicosis at the time of clinical onset or clinical worsening (s9(2) and s9(5)); treatment with a specified list of drugs at the time of clinical onset or clinical worsening (s9(3) and s9(6)); and inability to obtain appropriate clinical management for MPA (s9(7)). The Schedule defines the specified list of drugs (benzylthiouracil; carbimazole; hydralazine; methimazole; propylthiouracil) and defines terminal event (Schedule 1).

The requirement that any factor be related to the person's relevant service is explicit (s10(1)). "Relevant service" is defined in the Schedule to include particular categories under the VEA and MRCA: operational, peacekeeping, hazardous and British nuclear test defence service under the VEA, and warlike or non‑warlike service under the MRCA (Schedule 1). The instrument differentiates two use cases for the factors: ones that bear on initiating causation (clinical onset) and ones that bear on material contribution or aggravation (clinical worsening). Subsection 10(2) constrains subsections 9(4)-9(7) so that they "apply only to material contribution to, or aggravation of, microscopic polyangiitis where the person's microscopic polyangiitis was suffered or contracted before or during (but did not arise out of) the person's relevant service." Thus, the same factor may have different legal effect depending on whether the condition was first suffered in service or earlier.

Section 11 provides an interactional mechanism: if a factor in s9 refers to an injury or disease covered by another Statement of Principles, then the factors in that other Statement apply in accordance with its terms as in force from time to time (s11). That creates a cross‑referencing network for certain overlapping exposures or diseases.

Finally, death‑related concepts: s7(5) extends the meaning to include death from a terminal event or condition that was contributed to by the person's MPA. The Schedule sets out examples of terminal events (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function).

These concepts control how MPA claims are evaluated within the VEA/MRCA claims framework. The instrument translates medical associations into discrete legal tests (presence of listed factor(s), timing, relation to relevant service), rather than setting presumptions of causation per se.

This Statement of Principles directly affects claimants and decision‑makers in the VEA/MRCA claims systems and indirectly affects service organisations, medical practitioners and record‑keepers whose evidence will be used in claims assessments. The instrument "applies to a claim to which section 120A of the VEA or section 338 of the MRCA applies" (s5). That means any veteran, member of the Forces, or member of the Peacekeeping Forces who lodges a claim under those statutory provisions and asserts microscopic polyangiitis or death from MPA as service‑related will be assessed against this instrument.

The Schedule defines "relevant service" as a set of service categories under the VEA and MRCA (Schedule 1). Therefore, the population directly affected consists of persons who rendered operational service, peacekeeping service, hazardous service, British nuclear test defence service (VEA categories), or warlike or non‑warlike service under the MRCA (Schedule 1). For those veterans and former members, the instrument alters the legal medical test that decision‑makers will apply when evaluating whether a reasonable hypothesis exists linking their MPA to service.

Medical practitioners who diagnose and manage MPA will be affected in practice because their records and clinical opinions are the primary source material for establishing the elements in s9 and the timing of clinical onset or worsening. For example, diagnosing silicosis (s9(2), s9(5)), documenting exposure histories that support a cumulative 2,500 hours of respirable crystalline silica exposure (s9(1), s9(4)), recording treatment with a specified drug at the relevant times (s9(3), s9(6)), and documenting the adequacy or inadequacy of clinical management (s9(7)) are all evidential behaviours that will influence claim outcomes.

Decision‑makers within the Department of Veterans’ Affairs, the Repatriation Commission and Tribunal or Court review processes (to the extent claims go to review) will use the Statement as the medical link template, because the instrument is made under the statutory authority in s196B(2) of the VEA and is intended for use in VEA/MRCA claims (s3, s5). The Statement also affects other Statements of Principles through s11: where a factor in s9 refers to another injury or disease covered by a separate Statement, that other Statement’s factors apply as in force , this can alter evidentiary routes for those affected.

Finally, the instrument has no express application outside the VEA/MRCA claims regime. It does not create criminal offences, administrative fines or private rights of action; rather, its practical legal consequence is to define the medical‑causal criteria used within the specified veterans’ compensation frameworks (s5, s3).

The Statement itself does not create statutory obligations or rights in the sense of penalties or private causes of action, but it prescribes the evidentiary test and consequential rights within the VEA/MRCA claims regime. The central legal duty it places on decision‑makers is to apply the Statement’s factors when determining whether a reasonable hypothesis has been raised connecting MPA or death from MPA with the circumstances of a person’s relevant service. The instrument’s operative language is prescriptive as to the test: "At least one of the following factors must as a minimum exist before it can be said that a reasonable hypothesis has been raised" (s9). Thus, the duty of assessment is mechanistic: check whether any of the listed factors exists and whether it is related to relevant service (s10(1)).

For claimants, the Statement establishes the pathway by which they can satisfy the "reasonable hypothesis" threshold used in VEA/MRCA determinations. If a claimant can demonstrate the existence of at least one factor in s9 and connection to relevant service (s10(1)), then under the statutory scheme the reasonable hypothesis is raised. The right that flows from raising that reasonable hypothesis is the right to have the claim proceed under the standard application of the VEA/MRCA claim rules; the Statement does not itself specify benefit entitlements but establishes the medical link necessary in the claims process as used by decision‑makers.

The instrument imposes timing rules that affect the character of the duty: subsections 9(1)-(3) and 9(4)-(6) distinguish between factors relevant to clinical onset and factors relevant to clinical worsening, and subsection 10(2) limits 9(4)-(7) to cases where the condition was suffered or contracted before or during (but did not arise out of) relevant service. That requires decision‑makers to ascertain the chronology of disease relative to service. The Schedule defines "terminal event" and the list of "specified list of drugs", which establishes precisely what treatments count as a factor, constraining both the duty of decision‑makers and the claimant’s evidential task (Schedule 1).

There is also an interactional duty created by s11: where a factor in s9 refers to an injury or disease covered by another Statement of Principles, decision‑makers must apply the factors in that other Statement in accordance with its terms as in force from time to time. That duty compels cross‑referencing and may require consultation of multiple Statements.

Conversely, the instrument does not grant administrative enforcement powers, does not prescribe penalties, and does not set appeal rights beyond the usual statutory channels in the VEA and MRCA regimes. The Statement is a component of the statutory framework directing the medical causation inquiry; any procedural rights, appeals or remedies arise under the VEA or MRCA themselves rather than from this instrument’s text.

The Statement of Principles contains no express penalties, sanctions or criminal provisions. It is a medical linking determination made under subsection 196B(2) of the VEA (s3) and intended for use in the claims processes established by the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004 (s5). The instrument does not itself create enforcement mechanisms or disciplinary remedies.

Enforcement in the practical sense arises through application during claims adjudication under the VEA and MRCA. The Statement prescribes the medical causation test (s9 and s10) that decision‑makers must use when considering whether a reasonable hypothesis has been raised linking MPA or death from MPA to relevant service. If decision‑makers accept that a factor in s9 exists and is related to relevant service (s10(1)), then the reasonable hypothesis is established for that claim. Conversely, if no factor in s9 is shown to exist or none is related to relevant service, the Statement provides a basis to conclude that the reasonable hypothesis has not been raised. Those determinations feed directly into the benefit decision‑making process under the VEA and MRCA; any remedial enforcement or review mechanisms are the statutory review and appeal procedures set out in those Acts and not in this instrument.

Because the instrument repeals the previous Statement (s4), there may be administrative consequences in terms of re‑assessing existing or pending claims with the new instrument rather than the predecessor, subject to the procedural rules of the VEA/MRCA and transitional administration. The instrument itself does not stipulate transitional provisions; its effect is to be applied in the claims framework from its commencement (s2) and to be used in assessing claims to which the referenced sections of the VEA and MRCA apply (s5).

In short, penalties are not part of this instrument; the "enforcement" mechanism is its mandatory use by decision‑makers in the statutory claims processes for determining whether the reasonable hypothesis of service connection exists, and any contestation of a decision that applies the Statement will proceed through the normal appeal and review avenues in the VEA/MRCA scheme.

The instrument is made under the authority of subsection 196B(2) of the VEA (s3), and it explicitly states its application to claims under section 120A of the VEA or section 338 of the MRCA (s5). Therefore its primary legal interaction is with the VEA and MRCA claims frameworks. It provides the Repatriation Medical Authority’s determination of medical causation criteria that decision‑makers administering those Acts must apply when assessing whether a reasonable hypothesis exists that MPA or death from MPA is related to a person’s relevant service.

Section 11 creates a direct cross‑instrument interactional rule: if a factor in s9 refers to an injury or disease for which another Statement of Principles has been determined under subsection 196B(2) of the VEA, then the factors in that other Statement "apply in accordance with the terms of that Statement of Principles as in force from time to time" (s11). This means that where overlap exists , for example, if the factor refers to silicosis or another recognised occupational disease covered by a separate Statement , the other instrument’s determinants and thresholds will be integrated into the assessment for MPA claims via the cross‑reference. The text by itself does not list those other Statements; the operative rule requires decision‑makers to consult and apply externally determined Statements as they stand.

The instrument also addresses classification systems: s7(3)-(4) notes that while MPA attracts ICD‑10‑AM code M31.7, for the purpose of this Statement the meaning of MPA is the textual definition in s7(2). The instrument therefore limits reliance on diagnostic coding alone and requires assessment against the medical definition set out in the Statement, while recognising the ICD‑10‑AM as a classification reference (s7(3)-(4)).

Because the instrument embeds the definitions of "relevant service" and lists of specified drugs in its Schedule, it interacts with the statutory categories of service under the VEA and MRCA (Schedule 1). The Schedule’s definitions will determine whether a claimant’s service falls within the categories for which the Statement applies. The Statement does not modify the substantive entitlement or remuneration rules in the VEA or MRCA; it provides the medical causation input into application of those Acts. Interaction with other laws outside the VEA/MRCA framework is not provided for in the text; the instrument is a specialised medical‑causation instrument for the veterans’ compensation context.

Finally, the repeal of the previous Statement (s4) creates an interactional administrative change: decisions and assessments made under the prior Statement of Principles No. 13 of 2011 may be reviewed or reassessed in light of the new instrument to the extent relevant under the governing procedural rules in the VEA/MRCA, but the instrument itself does not stipulate transitional treatment or override the procedural rules in those Acts.

The instrument itself is a discrete Repatriation Medical Authority determination dated 18 October 2019 (page header) and is designated Statement of Principles No. 90 of 2019 (title). It commences operation on 18 November 2019 (s2). The only amendment action recorded within the instrument is repeal of an earlier Statement: "The Statement of Principles concerning microscopic polyangiitis No. 13 of 2011 (Federal Register of Legislation No. 2010L03260) made under subsection 196B(2) of the VEA is repealed" (s4). That is the sole express amendment or repeal recorded.

The instrument is made under the specific statutory power in subsection 196B(2) of the VEA (s3). The Schedule updates and restates definitions relevant to MPA claims, including the list of specified drugs, the definition of terminal event, and the precise categories comprising "relevant service". Those definitional particulars constitute the substantive content of the instrument and thereby function as the operative amendments relative to previous versions: they replace the prior set of definitions and factors for MPA contained in Statement No. 13 of 2011.

No further amendment history, sequential changes, or later variations are recorded in the instrument provided. The statement contains the Repatriation Medical Authority’s seal and the Chairperson’s name (Professor Nicholas Saunders AO), indicating formal execution and sign‑off. There are no transitional provisions or savings clauses recorded within this instrument; its commencement date (s2) and repeal provision (s4) are the only temporal mechanics given.

If users require a complete legislative amendment chronology or any post‑2019 amendments, that information is not included in this instrument and would need to be sought from the Federal Register of Legislation or the Repatriation Medical Authority’s published determinations. As drafted, the instrument updates the MPA Statement of Principles framework by supplanting the 2011 Statement with the text provided here, effective from 18 November 2019 (s2, s4).

This instrument contains no litigation history. It is a Repatriation Medical Authority Statement of Principles and the text does not recite any judicial decisions, administrative appeals, or tribunal determinations. The instrument is a medical‑causation determination intended to be used in adjudicating claims under the VEA and MRCA (s3, s5), and the document itself records only the Authority’s view of the medical‑scientific evidence that underlies the factors (s8).

Because the instrument is an evidentiary template for use in statutory claims, disputes about its application or about whether a particular claimant has established a factor or a relationship to relevant service may arise in the administrative decision‑making and review processes available under the VEA and MRCA. Such litigation or review would be conducted under the procedural and review mechanisms of those Acts. However, the instrument does not record any specific cases, appeals or judicial pronouncements about the application of these particular factors, nor does it include references to case law or prior litigated interpretations within its text.

For readers seeking jurisprudential treatment of the Statement’s operation in real claims, this instrument does not furnish that material; the presence or absence of litigation, the outcomes of any appeals, or the interpretive positions taken by courts or tribunals are not set out here. Any assessment of how courts or tribunals have treated this Statement, or of precedents that interpret its provisions, would require examination of external adjudicative records and is not contained in this text.

Applying this Statement contains several specific technical pitfalls and timing traps that arise directly from the text. The following items are matters where practitioners often need to pay close attention because small factual differences change whether a factor operates as written.

• Cumulative exposure threshold is prescriptive. Inhalation of respirable crystalline silica qualifies only if it occurred "at the time material containing crystalline silica was being ... produced, excavated, drilled, cut or ground, or used in construction, manufacturing, cleaning or blasting" for a cumulative period of at least 2,500 hours before the clinical onset (s9(1)) or before clinical worsening (s9(4)). The instrument requires evidence of both the specific activity contexts listed and the cumulative hours threshold. An undifferentiated assertion of "silica exposure" without placing it into one of these enumerated activities and quantifying the 2,500 hours will not, by the instrument’s terms, establish the factor.

• Diagnosis must meet the instrument’s medical definition, not merely an ICD code. The instrument notes that microscopic polyangiitis attracts ICD‑10‑AM code M31.7, but expressly states that for the purposes of the Statement the meaning of MPA is that given in subsection 7(2) (s7(2)-(3)). Therefore, relying solely on diagnostic coding without clinical documentation that the disease matches the textual definition (necrotising non‑granulomatous vasculitis with few or no immune deposits predominantly affecting small vessels) risks a failed application.

• Timing of onset versus worsening matters. Subsections 9(1)-(3) address factors at the time of clinical onset; subsections 9(4)-(6) address factors at the time of clinical worsening (s9). Critically, subsection 10(2) limits the latter group (9(4)-9(7)) to cases of material contribution or aggravation where the person's MPA "was suffered or contracted before or during (but did not arise out of) the person's relevant service." That means if the MPA arose out of service (i.e. originated as a result of service) the clinical‑worsening factors have different application; practitioners must carefully establish whether the disease was suffered or contracted before, during, or as a result of service.

• Specified drugs are a short, closed list. The Schedule identifies five drugs by name (benzylthiouracil; carbimazole; hydralazine; methimazole; propylthiouracil). Only treatment with those drugs at the time of clinical onset or clinical worsening is a listed factor (s9(3), s9(6); Schedule 1). Treatment with other drugs is not captured by this factor unless another Statement of Principles or medical evidence is applicable via s11.

• "Inability to obtain appropriate clinical management" is a listed factor but is open to evidential contention. Subsection 9(7) lists this as a factor without statutory elaboration. The term is not defined in the Schedule, so assessors will need to rely on clinical records, contemporaneous attempts to obtain management, and possibly expert opinion to determine whether the claimant lacked appropriate management and whether that inability materially contributed to MPA onset or worsening.

• Death claims require MPA contribution to a terminal event. Subsection 7(5) extends MPA to include "death from a terminal event or condition that was contributed to by the person's microscopic polyangiitis" (s7(5)). The Schedule defines "terminal event" by example (pneumonia, respiratory failure, cardiac arrest, circulatory failure, cessation of brain function). For death claims, it is not sufficient to show a terminal event alone; the MPA must have contributed to that terminal event.

• Cross‑application with other Statements can alter evidence routes. If a factor in s9 refers to an injury or disease covered by another Statement of Principles, s11 requires that the factors in that other Statement apply as in force from time to time. Practitioners must identify and apply any such other Statements when a factor overlaps with another disease (for example, if silicosis has its own Statement, that Statement’s evidentiary criteria must be applied).

• Relation to "relevant service" is an independent requirement. Even if a listed factor exists, subsection 10(1) requires that the factor be related to the person's relevant service. The instrument’s Schedule defines the different types of relevant service; proving service type and connecting the exposure or treatment to that service are distinct evidential tasks.

These items are not interpretive dicta; they arise from the instrument’s textual mechanics and therefore are the critical practical traps to watch when preparing or assessing claims under this Statement.

Compliance here means assembling and presenting the evidence that the Statement requires in order to raise the reasonable hypothesis that MPA, or death from MPA, is related to relevant service. The instrument sets out discrete elements; compliance is achieved by matching documentary and clinical evidence to those elements and to the timing and relationship rules.

1. Establish the clinical diagnosis against the instrument’s medical definition (s7(2)). Obtain and collate contemporaneous medical records showing histopathology, serology (for example ANCA status, where present), radiology and nephrology/pulmonology reports that support the diagnosis of a "necrotising non‑granulomatous vasculitis with few or no immune deposits predominantly affecting small vessels." Do not rely solely on the ICD‑10‑AM code M31.7, because the instrument requires the textual meaning in s7(2) (s7(3)).

2. Determine the relevant event timing: clinical onset and any subsequent clinical worsening. The instrument differentiates factors relevant to onset (s9(1)-(3)) from those relevant to worsening (s9(4)-(6)). Prepare a timeline linking service periods, first clinical manifestations, diagnosis dates, and dates of any documented clinical deterioration.

3. Prove the service category and dates. Use service records to establish that the person rendered one of the categories in the Schedule’s definition of relevant service (operational, peacekeeping, hazardous, British nuclear test defence service under the VEA; warlike or non‑warlike under MRCA) so that s10(1) can be satisfied. The claimant must show that the exposure or other factor relied upon is connected to that service.

4. If relying on silica exposure, document the exposure context and quantify cumulative hours. For s9(1) or s9(4), evidence must show inhalation of respirable crystalline silica while material containing crystalline silica was being produced, excavated, drilled, cut or ground, or used in construction/manufacturing/cleaning/blasting, and that the exposure cumulated to at least 2,500 hours before the relevant clinical date. Evidence can include trade records, unit logs, witness statements, occupational exposure records, employer records, and any contemporaneous documentation of duties and tasks; expert occupational hygiene opinion may assist in translating tasks into cumulative exposure hours.

5. If relying on silicosis, obtain objective diagnostic proof. For s9(2) or s9(5), establish that silicosis was present at the time of clinical onset or worsening. Provide imaging, respiratory physician reports, histology if available, and any compensation or medical records diagnosing silicosis.

6. If relying on specified drugs, show treatment with a listed drug at the required time. For s9(3) or s9(6), present pharmacy, hospital, prescribing GP or specialist records showing treatment with any of the specified drugs (benzylthiouracil, carbimazole, hydralazine, methimazole, propylthiouracil) at the time of clinical onset or clinical worsening. The Schedule’s closed list means evidence must match those names exactly.

7. If relying on inability to obtain appropriate clinical management (s9(7)), assemble evidence documenting attempts to access care and the reasons why appropriate management was not obtained. Clinical notes, referral correspondence, appointment records, geographic or deployment constraints on access to care, and contemporaneous communications may be necessary. Because the term is not defined in the Schedule, contemporaneous clinical commentary and expert opinion on what constituted an appropriate standard of care and why it was not accessible will strengthen the claim.

8. For death claims, link MPA to the terminal event. If the claim concerns death from MPA, ensure medical cause‑of‑death documentation and clinical records demonstrate that MPA contributed to the terminal event (s7(5) and Schedule). Death certificates, autopsy reports, and treating clinicians’ opinions should indicate the contribution of MPA to the fatal sequence.

9. Where a factor in s9 refers to a disease covered by another Statement, identify and apply that Statement’s factors in parallel (s11). For example, if the factor relies on silicosis but the assessment of silicosis depends on another Statement, secure and apply that other Statement’s evidentiary criteria.

10. Prepare expert opinion that links the factor to relevant service and to the clinical event, addressing timing and causation. The instrument requires the factor to be related to relevant service (s10(1)); an expert providing a causal opinion that explicitly addresses how the documented exposure or treatment during the relevant service period could have caused or materially contributed to the onset or worsening of MPA will align the evidence with the instrument’s requirements.

11. Assemble a concordant, chronological claim bundle. Ensure records clearly map service periods to exposures/treatments, and map those to clinical dates of onset/worsening and to diagnostic evidence consistent with the Statement’s definition.

12. For decision‑makers, apply s9 and s10 mechanically. Confirm that at least one s9 factor exists, that the medical definition in s7(2) is met, and that the factor is related to the relevant service as defined in the Schedule (s10(1)). If a factor refers to another Statement, apply s11.

Following these steps aligns fact‑finding and evidence collection with the text of the Statement, which is the mechanism by which a reasonable hypothesis is raised in the VEA/MRCA claims context.